Allogene Therapeutics, Inc. (ALLO)

NASDAQ: ALLO · Real-Time Price · USD
2.350
+0.190 (8.80%)
Jan 7, 2025, 4:00 PM EST - Market closed
8.80%
Market Cap 492.73M
Revenue (ttm) 43,000
Net Income (ttm) -283.43M
Shares Out 209.67M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,208,946
Open 2.150
Previous Close 2.160
Day's Range 2.150 - 2.405
52-Week Range 1.780 - 5.780
Beta 0.85
Analysts Buy
Price Target 10.06 (+328.09%)
Earnings Date Nov 7, 2024

About ALLO

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 fo... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 11, 2018
Employees 233
Stock Exchange NASDAQ
Ticker Symbol ALLO
Full Company Profile

Financial Performance

In 2023, Allogene Therapeutics's revenue was $95,000, a decrease of -39.10% compared to the previous year's $156,000. Losses were -$327.27 million, -3.86% less than in 2022.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ALLO stock is "Buy." The 12-month stock price forecast is $10.06, which is an increase of 328.09% from the latest price.

Price Target
$10.06
(328.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...

22 days ago - GlobeNewsWire

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...

26 days ago - GlobeNewsWire

Allogene Therapeutics Announces Participation in December Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...

7 weeks ago - GlobeNewsWire

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...

7 weeks ago - GlobeNewsWire

Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affair and Brand Strategy Officer David...

2 months ago - Seeking Alpha

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...

2 months ago - GlobeNewsWire

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...

2 months ago - GlobeNewsWire

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...

2 months ago - GlobeNewsWire

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...

2 months ago - GlobeNewsWire

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Allogene Therapeutics, Inc. (ALLO, Financial) saw a significant drop in its stock price, falling 5.06% to $2.54 per share. The trading volume reached 1.41 million shares, with a turnover rate of 0.67%...

3 months ago - GuruFocus

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC...

3 months ago - GlobeNewsWire

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Allogene Therapeutics is a clinical-stage biotech developing allogeneic CAR T therapies for cancer and autoimmune diseases, with a focus on Cema-cel for LBCL. ALLO's advanced gene-editing platforms, l...

4 months ago - Seeking Alpha

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Christine Cassiano - Executive Vice President, Chief Corporate Officer and IR...

5 months ago - Seeking Alpha

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...

5 months ago - GlobeNewsWire

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...

5 months ago - GlobeNewsWire

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...

5 months ago - GlobeNewsWire

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

6 months ago - GlobeNewsWire

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., June 20, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of alloge...

7 months ago - GlobeNewsWire

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

Allogene Therapeutics, Inc. initiation of phase 2 ALPHA3 study, using cema-cel for the treatment of patients with 1st-line large B-cell lymphoma, expected in mid-2024 with two data analysis in 2026. R...

7 months ago - Seeking Alpha

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

8 months ago - GlobeNewsWire

Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2024 Earnings Conference Call May 13, 2024 5:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affairs & Brand Strategy Officer David Cha...

8 months ago - Seeking Alpha

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

8 months ago - GlobeNewsWire

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

8 months ago - GlobeNewsWire

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

8 months ago - GlobeNewsWire

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

SOUTH SAN FRANCISCO, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC...

9 months ago - GlobeNewsWire